Orfeas-Petros Varvarelis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Orfeas-Petros Varvarelis has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Hernandez Jerez
Department of Legal Medicine and Toxicology, University of Granada School of Medicine, Granada, Spain; Instituto de Investigación Biosanitaria, ibs.GRANADA, Granada, Spain; CIBER Epidemiology and Public Health (CIBERESP), Madrid, Spain
1 shared publication Aristidis Tsatsakis
Center of Toxicology Science & Research, Medical School, University of Crete, 71003, Heraklion, Crete, Greece
1 shared publication- Athina-Maria Aloizou
Department of Neurology, St. Josef-Hospital, University Hospital of the Ruhr University Bochum, Bochum, Germany
1 shared publication Dimitrios P. Bogdanos
Department of Rheumatology and Clinical Immunology, University Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
1 shared publicationDimitrios Rikos
Department of Neurology, University Hospital of Larissa Greece, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece
1 shared publication- Dorothea Tsekoura
2nd Department of Surgery, Aretaieio University Hospital, National and Kapodistrian University of Athens, Athens, Greece
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Peertechz Publications Private Limited in Global Journal of Cancer Therapy
- Vol. 12 (1) , 4-19
Beyond Troponins: Emerging Biomarkers for Early Detection of Chemotherapy-Induced Cardiotoxicity in Breast Cancer
Although modern breast cancer therapies have significantly improved long-term survival, reliable tools for the early detection and prediction of Cancer Therapy-Related Cardiac Dysfunction (CTRCD) remain essential. Cardiovascular toxicity encompasses a broad spectrum of manifestations, ranging from asymptomatic myocardial dysfunction to heart failure, ischemic heart disease, valvular abnormalities, arrhythmias, hypertension, and thromboembolic events. Anthracyclines and radiation therapy are the most well-established cardiotoxic treatments. Anthracycline-induced cardiotoxicity demonstrates a dose-dependent and often irreversible pattern (Type I cardiotoxicity), primarily mediated by oxidative stress and mitochondrial injury. In contrast, HER-2 targeted therapies are associated with reversible myocardial dysfunction (Type II cardiotoxicity), mainly through the disruption of the ErbB2 signaling pathway. Newer therapies, including anti-VEGF agents and endocrine therapies combined with CDK4/6 inhibitors, further expand the spectrum of cardiovascular risks. Current guidelines support the use of left ventricular ejection fraction, troponins, and natriuretic peptides for cardiotoxicity monitoring. However, emerging biomarkers, including myeloperoxidase, matrix metalloproteinases, galectin-3, inflammatory markers, and microRNAs, have shown potential for the early detection of myocardial injury. This review summarizes the current evidence regarding the mechanisms, clinical features, and risk factors of cardiotoxicity associated with breast cancer therapy. It further evaluates both established and novel biomarkers and highlights the clinical value of integrating them with advanced imaging modalities to improve the early detection and monitoring of cardiac remodeling. Further research is required to validate these approaches for clinical use (Graphical abstract).
- 1 January 2026
- Published by Peertechz Publications Private Limited in Global Journal of Cancer Therapy
- Vol. 12 (1) , 4-19
Open AccessBeyond Troponins: Emerging Biomarkers for Early Detection of Chemotherapy-Induced Cardiotoxicity in Breast Cancer
Although modern breast cancer therapies have significantly improved long-term survival, reliable tools for the early detection and prediction of Cancer Therapy-Related Cardiac Dysfunction (CTRCD) remain essential. Cardiovascular toxicity encompasses a broad spectrum of manifestations, ranging from asymptomatic myocardial dysfunction to heart failure, ischemic heart disease, valvular abnormalities, arrhythmias, hypertension, and thromboembolic events. Anthracyclines and radiation therapy are the most well-established cardiotoxic treatments. Anthracycline-induced cardiotoxicity demonstrates a dose-dependent and often irreversible pattern (Type I cardiotoxicity), primarily mediated by oxidative stress and mitochondrial injury. In contrast, HER-2 targeted therapies are associated with reversible myocardial dysfunction (Type II cardiotoxicity), mainly through the disruption of the ErbB2 signaling pathway. Newer therapies, including anti-VEGF agents and endocrine therapies combined with CDK4/6 inhibitors, further expand the spectrum of cardiovascular risks. Current guidelines support the use of left ventricular ejection fraction, troponins, and natriuretic peptides for cardiotoxicity monitoring. However, emerging biomarkers, including myeloperoxidase, matrix metalloproteinases, galectin-3, inflammatory markers, and microRNAs, have shown potential for the early detection of myocardial injury. This review summarizes the current evidence regarding the mechanisms, clinical features, and risk factors of cardiotoxicity associated with breast cancer therapy. It further evaluates both established and novel biomarkers and highlights the clinical value of integrating them with advanced imaging modalities to improve the early detection and monitoring of cardiac remodeling. Further research is required to validate these approaches for clinical use (Graphical abstract).
- 7 February 2023
- Published by Elsevier in Environmental Research
- Vol. 229, 115442
Pesticides and tremor: An overview of association, mechanisms and confounders
- 7 February 2023
- Published by Elsevier in Environmental Research
- Vol. 229, 115442
Pesticides and tremor: An overview of association, mechanisms and confounders